Tripeptide-10 Citrulline
A cosmetic peptide engineered to imitate decorin, the proteoglycan that keeps dermal collagen fibrils thin and evenly sized. Sold as Decorinyl, it targets collagen organisation rather than collagen quantity — a genuinely distinct pitch resting on an unusually small evidence base: two PubMed records in total, one in vitro paper from the company that invented it and one human trial with six people per arm.
Tripeptide-10 citrulline is a tiny lab-made peptide designed to copy part of decorin, a natural molecule that stops collagen fibres in skin from clumping into thick, disorganised bundles. The idea is to improve the quality of the collagen you already have rather than make more of it. Despite the name it has four amino acids, not three. Only two studies about it exist in the medical literature, and the single human trial tested six people per group.
What is Tripeptide-10 Citrulline?
Tripeptide-10 citrulline is a synthetic cosmetic peptide with the sequence lysine-aspartate-isoleucine-citrulline. It has the molecular formula C22H42N8O7, a molecular weight of about 530 daltons, CAS number 960531-53-7 and UNII 2732R0E76W, and appears in the European Commission's CosIng database under reference 83256 with a single declared function: skin conditioning. The trade name under which formulators buy it is Decorinyl, from Lipotec in Gava, Barcelona — now part of Lubrizol Life Science Beauty. The name is a small puzzle worth clearing up immediately, because it misleads almost everyone who reads it. Tripeptide-10 citrulline contains four amino acid residues, not three. The INCI naming convention counts only the standard proteinogenic residues — here lysine, aspartate and isoleucine, which together constitute the separately registered INCI ingredient Tripeptide-10 — and names the non-standard fourth residue, citrulline, alongside. The peer-reviewed paper that introduced the molecule says so in its own title: it describes a new decorin-like tetrapeptide. The second thing the name misleads about is citrulline. The citrulline in this molecule is a residue bonded into a peptide chain, chemically a urea-modified ornithine. It is not free L-citrulline, it is not absorbed, it does not enter the urea cycle, and it has nothing to do with the nitric-oxide and blood-flow pharmacology that makes citrulline a familiar sports supplement. The resemblance is nomenclature, not biology. The design target is decorin: a small leucine-rich proteoglycan that binds collagen type I along the fibril surface and limits lateral growth, keeping fibrils thin and uniform in diameter. Functional decorin declines with age, and the resulting fibril disorganisation is one structural contributor to the loss of skin suppleness. Tripeptide-10 citrulline was engineered from decorin's own collagen-binding sequence as a low-molecular-weight substitute for that interaction.
What Tripeptide-10 Citrulline Is Investigated For
Tripeptide-10 citrulline has the smallest published footprint of any peptide in this directory with a commercial presence of its size. A PubMed search returns exactly two records. The first is the discovery paper (Puig, Anton and Mangues, International Journal of Cosmetic Science 2008), written by Lipotec researchers. They identified two tetrapeptide sequences as decorin's specific collagen-binding sites, synthesised a focused library of candidates mimicking those sequences, screened them in an in vitro collagen fibrillogenesis assay, and reported that the candidate given the INCI name Tripeptide-10 Citrulline performed best — regulating fibrillogenesis and producing collagen fibres that were thinner and more uniform in diameter. Their framing is the one the ingredient has carried ever since: skin collagen quality is addressed rather than skin collagen quantity. It is an in vitro study by the company that sells the ingredient, and nobody has independently repeated it. The second is the only human trial (Raikou et al., Journal of Cosmetic Dermatology 2017), and it has the virtue of independence — the authors are at the Technological Educational Institute of Athens and the University of Athens, with no supplier affiliation. Twenty-four volunteers were randomised across four groups for 60 days: acetyl hexapeptide-3 plus tripeptide-10 citrulline, tripeptide-10 citrulline alone, acetyl hexapeptide-3 alone, and neither. That is six people per arm. Skin microtopography parameters (cR2 and cR3, measured with a Visioscan) and transepidermal water loss (measured with a Tewameter) were the endpoints. Several between-group comparisons reached nominal significance at 20, 40 and 60 days, and the authors concluded that they had provided clinical evidence for the antiwrinkle efficacy of tripeptide-10 citrulline and possibly for an effect on transepidermal water loss. They also stated plainly that the mechanism by which the two peptides might act synergistically was not clear from their study. So the honest position is this: a mechanistically coherent, genuinely differentiated idea — target fibril organisation rather than collagen synthesis — supported by one industry in vitro paper and one independent six-per-arm human study using instrument surrogates rather than clinical wrinkle grading. That is a reasonable basis for interest and an unreasonable basis for confidence.
History & Discovery
The ingredient comes out of Lipotec, a Spanish peptide house founded in Gava near Barcelona that produced several of the cosmetic peptides now in wide use and was acquired by Lubrizol in 2012, becoming part of what is today Lubrizol Life Science Beauty. Its origin is unusually well documented for a cosmetic active, because the development programme was published rather than left to a supplier brochure. Puig, Anton and Mangues set out the logic in the International Journal of Cosmetic Science in 2008: decorin regulates collagen fibrillogenesis by binding the fibril and preventing excessive bundle-like aggregation; functional decorin is lost with age, leaving disrupted fibres and reduced skin tensile strength; therefore a low-molecular-weight substitute for decorin's collagen-binding activity would be a plausible cosmetic active. They worked from two tetrapeptide sequences previously identified as decorin's specific binding sites on collagen, engineered variants intended to improve affinity, built a focused library restricted to tetrapeptides mimicking those sequences, and screened the candidates in a collagen fibrillogenesis assay. The winner was registered with the INCI name Tripeptide-10 Citrulline and commercialised as Decorinyl. What distinguishes this history from much of the cosmetic peptide field is that the rational-design step is real and published: the sequence was derived from a mapped protein-protein interaction rather than selected empirically and rationalised afterwards. What it shares with the rest of the field is what happened next. Nearly two decades on, the ingredient has acquired commercial reach far out of proportion to its literature — one independent human trial, published nine years after the discovery paper, with six participants per arm. No laboratory outside the company has repeated the fibrillogenesis work, and no clinical programme was ever built on it.
How It Works
Collagen in young skin is organised into thin, evenly sized fibrils, kept that way by a protein called decorin that coats the fibril surface and stops it growing too thick. Decorin function declines with age and the fibrils become coarse and disorganised. Tripeptide-10 citrulline is a four-residue fragment built to copy decorin's collagen-binding site, with the aim of restoring that organising effect.
Decorin is a small leucine-rich proteoglycan comprising a roughly 40-kilodalton horseshoe-shaped core protein with twelve leucine-rich repeats and a single glycosaminoglycan chain. Its concave inner surface binds collagen type I, and it docks at a specific site near the carboxy-terminal end of the collagen monomer. Functionally it acts as a regulator of fibrillogenesis: by occupying the fibril surface it limits lateral accretion of new collagen monomers, constraining fibril diameter and keeping the population narrow and uniform. The consequences of losing that regulation are not theoretical — targeted disruption of the decorin gene in mice produces abnormal collagen fibril morphology, with coarse and irregular fibril outlines, and skin with markedly reduced tensile strength, a phenotype first described by Danielson and colleagues in 1997. Decorin also undergoes structural change with age in human skin, which is the premise on which a decorin-mimetic cosmetic ingredient rests. Tripeptide-10 citrulline was derived directly from that interaction. The Lipotec group identified two tetrapeptide sequences as decorin's specific collagen-binding sites, synthesised a focused library of tetrapeptides mimicking them with the intent of improving binding affinity, and screened candidates in an in vitro type I collagen fibrillogenesis assay. The winning candidate, lysine-aspartate-isoleucine-citrulline, reproduced decorin-like behaviour in that assay: it regulated fibrillogenesis and influenced fibril diameter, producing thinner and more uniform fibres. The proposed downstream benefit is better cohesion between collagen fibres and therefore greater skin suppleness. Three limits on this mechanism should be stated alongside it. First, a 530-dalton tetrapeptide reproduces at most one binding interface of a multidomain proteoglycan; decorin's leucine-rich repeat architecture and its glycosaminoglycan chain contribute to collagen spacing and to growth-factor sequestration that no tetrapeptide can imitate. Second, the entire mechanistic case comes from a cell-free fibrillogenesis assay — purified collagen in solution, not dermis — and no study has demonstrated altered fibril diameter in living human skin after topical application. Third, the mechanism presupposes the peptide reaches the dermal extracellular matrix in meaningful quantity, and no penetration data have been published for it. The mechanism is coherent and specific, which distinguishes it favourably from much of the cosmetic peptide field; it is also almost entirely untested where it would need to be true.
Evidence Snapshot
Human Clinical Evidence
Limited, and quantifiably so: one randomised controlled trial with 24 participants split across four arms, six per arm (Raikou 2017). Over 60 days it measured skin microtopography parameters and transepidermal water loss with instruments and found several nominally significant between-group differences, leading the authors to conclude that antiwrinkle efficacy had been demonstrated for tripeptide-10 citrulline. The trial is independent of the ingredient supplier, which is a point in its favour. It is also underpowered by any conventional standard, relies on surrogate instrument endpoints rather than clinical or photographic wrinkle grading, and has never been replicated.
Animal / Preclinical
None. No animal study of tripeptide-10 citrulline has been published. The relevant animal evidence is one step removed and concerns the target rather than the peptide: decorin-null mice develop abnormal collagen fibril morphology and fragile skin, establishing that the organising function the peptide aims to replace is genuinely load-bearing for skin mechanics.
Mechanistic Rationale
Moderate, and better specified than most cosmetic peptides. Decorin's role in constraining collagen fibril diameter is well established across three decades of matrix biology, including knockout phenotypes and structural modelling of the decorin-collagen interface, and the peptide was rationally derived from the mapped binding sequence rather than reverse-engineered from a marketing claim. What holds the rating back is that the supporting assay was cell-free and performed by the supplier, no independent laboratory has repeated it, and the step from a fibrillogenesis tube assay to collagen architecture in living dermis is a long one that nobody has attempted to bridge.
Research Gaps & Open Questions
What the current literature has not yet settled about Tripeptide-10 Citrulline:
- 01No independent replication of the founding result. The in vitro fibrillogenesis finding that justifies the entire ingredient comes from a single paper by the company that sells it, published in 2008. No laboratory outside Lipotec has repeated the collagen fibrillogenesis assay or confirmed that this sequence behaves as a decorin mimetic.
- 02No skin-penetration data whatsoever. The proposed mechanism requires the peptide to reach dermal collagen, yet no published study measures whether a 530-dalton hydrophilic peptide with charged lysine and aspartate side chains and no lipid tail crosses the stratum corneum in useful quantity. Every downstream claim rests on an assumption nobody has tested.
- 03No demonstration of the mechanism in living skin. Thinner, more uniform fibrils were observed in a cell-free assay with purified collagen. Whether topical application alters collagen fibril diameter or organisation in human dermis has never been assessed — it would require biopsy and electron microscopy, and no such study has been done.
- 04No adequately powered human trial. The single clinical study randomised six participants per arm, used instrument surrogates rather than clinical or photographic wrinkle grading, and has never been repeated. A properly powered, vehicle-controlled, blinded trial of the single ingredient does not exist.
- 05No validated endpoint for the claim being made. The ingredient's distinctive proposition is better collagen quality rather than more collagen, and no non-invasive human measurement of collagen fibril organisation is available. This means the central claim is currently untestable by the methods cosmetic trials use, and skin-roughness instruments are several inferential steps away from fibril architecture.
- 06No dose-response relationship, and therefore no way to evaluate a product. Without knowing what concentration produces an effect, a disclosed concentration on a label is uninterpretable, and the typical sub-one-percent inclusion cannot be judged adequate or token.
- 07No long-term data. The longest study ran 60 days. Whether continued use produces cumulative benefit, plateaus, or has any effect on dermal matrix over the timescales on which collagen actually turns over is entirely unknown.
Forms & Administration
Tripeptide-10 citrulline appears only as an ingredient in topical leave-on cosmetics — serums, essences, eye products and moisturisers. There is no injectable, oral or professional-procedure form, and no legitimate reason to seek one. It is supplied to formulators as Decorinyl, a dilute aqueous solution, and incorporated into the water phase of a finished product. Being an unmodified hydrophilic peptide it is water-soluble and pH-stable across the mildly acidic to neutral range typical of cosmetic emulsions, and it carries no palmitoyl or other lipid tail of the kind used on Matrixyl-family peptides to assist penetration. In practice it is rarely sold alone. Commercial products almost always pair it with other peptides — acetyl hexapeptide-3, acetyl octapeptide-3, palmitoyl pentapeptide-4 — or with conventional actives, which is also why no finished-product study has ever isolated its contribution. The one published human trial formulated it as a single-peptide preparation precisely so it could be compared against the combination, and that remains the only setting in which it has been tested on its own.
Dosing & Protocols
The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.
Typical Range
Not established. Suppliers provide the peptide as a dilute solution incorporated at low percentages of finished formula, placing actual peptide content at a fraction of a percent. No published dose-response data exist.
Frequency
Typically once or twice daily as part of a leave-on routine, in line with the serum or moisturiser carrying it.
Timing Considerations
No specific timing requirements: can be administered at any time of day, with or without food, and is not tied to exercise timing. Consistency matters more than the specific clock — dose at roughly the same time each day (or same day each week, for weekly protocols) to keep exposure steady.
Protocol Notes
Dosing of a cosmetic peptide is formulation-dependent and largely unverifiable by the person using it. INCI labelling lists ingredients in descending order of concentration only down to one percent; beneath that, order is unregulated, so a peptide appearing late in a list may be present anywhere from a meaningful fraction of a percent to a token amount. Because no dose-response relationship has been published for tripeptide-10 citrulline, even full disclosure would not tell you whether a product contains an effective quantity. Application follows ordinary topical practice: apply to clean skin, lighter water-based layers before heavier occlusive ones, and allow absorption before layering. The human trial ran for 60 days with measurements at 20, 40 and 60 days, and several comparisons were already significant at 20 days — so if a timescale is to be inferred from the only evidence available, it is weeks rather than days, assessed over about two months. One practical point follows from the mechanism. Because the claimed action is on dermal collagen organisation rather than on the epidermis, any benefit depends entirely on delivery to the dermis, and no penetration data exist. Nothing about the formulation of a given product can be assumed to solve that problem, and a peptide that does not reach the dermal matrix cannot act on fibrillogenesis however elegant its design.
Tripeptide-10 citrulline is a cosmetic ingredient, not a drug. It is not approved to treat any skin condition, and no regulator has evaluated the claims made for it.
Timeline of Effects
Onset
Nothing is measurable in days. The only human trial took its first measurements at 20 days, where several between-group differences in skin microtopography and transepidermal water loss were already nominally significant. Any mechanism acting on dermal collagen fibril architecture would be expected to operate over collagen's turnover timescale, which is months rather than weeks — so an early surface measurement likely reflects hydration and barrier changes attributable to the formulation rather than the structural effect the peptide is designed to produce.
Peak Effect
Undetermined. The single trial stopped at 60 days with differences still present, which establishes nothing about where benefit plateaus — no longer study has been conducted. If the stated mechanism is real, the relevant timescale is that of dermal matrix remodelling, and a two-month trial would be observing an effect still in progress. In the absence of any longer data, claims about peak benefit at a particular week are invention.
After Discontinuation
Not studied at all. No trial has followed participants after stopping. Reasoning from mechanism rather than data: a peptide that regulates fibrillogenesis only while present would stop influencing newly forming fibrils once discontinued, with existing fibril architecture persisting until it turns over. That predicts gradual regression over months rather than an abrupt loss, but it is an inference from the proposed mechanism, not an observation.
Common Questions
Why is it called a tripeptide when it has four amino acids?
Because INCI nomenclature counts only the standard proteinogenic amino acids. The lysine-aspartate-isoleucine core is the registered ingredient Tripeptide-10; citrulline, which is not one of the twenty amino acids the body builds proteins from, is named separately rather than counted into the peptide number. The result is an ingredient whose name says three and whose structure has four, and the 2008 paper that introduced it calls it a tetrapeptide in its title. Nothing is wrong with the ingredient — the convention is just a poor guide to its chemistry.
Does tripeptide-10 citrulline increase collagen?
No, and claiming it does misses the point of the molecule. The entire design premise is that it acts on collagen organisation rather than collagen production. Decorin, the protein it imitates, binds along the surface of collagen type I fibrils and limits how thick they grow; without enough functional decorin, fibrils aggregate into coarse, irregular bundles and the tissue loses tensile quality. The in vitro data report thinner, more uniform fibrils, not more collagen. This genuinely separates it from matrikine peptides such as Matrixyl or Syn-Coll, whose stated mechanism is upregulating procollagen synthesis. If a product claims tripeptide-10 citrulline boosts collagen production, it is describing a different ingredient's mechanism.
Is the citrulline in it the same as the citrulline in sports supplements?
No. The citrulline here is an amino acid residue incorporated into a four-residue peptide chain, applied topically at cosmetic concentrations. L-citrulline and citrulline malate, the sports supplements, are free amino acids taken orally in gram quantities, converted to arginine and feeding nitric-oxide synthesis for vasodilation and exercise performance. Tripeptide-10 citrulline is not absorbed as free citrulline, does not enter the urea cycle, and has no vascular or nitric-oxide mechanism. The shared word is the only thing the two have in common.
Is there any evidence it actually works on human skin?
One trial, and you should know its size. Raikou and colleagues (2017) randomised 24 volunteers into four groups — six people per arm — for 60 days, measuring skin microtopography and transepidermal water loss with instruments rather than grading wrinkles clinically or photographically. Several between-group comparisons reached nominal significance, and the authors concluded they had shown antiwrinkle efficacy for tripeptide-10 citrulline. To their credit the group is academic and independent of the supplier, which is more than can be said for most cosmetic-peptide literature. But six per arm, instrument surrogate endpoints and no replication anywhere means this supports plausibility rather than efficacy.
Can a 530-dalton peptide get through the skin barrier?
This is the central unanswered question and no published study addresses it for this molecule. Peptides of this size face a real obstacle: the stratum corneum favours small, lipophilic molecules, and tripeptide-10 citrulline is hydrophilic with charged lysine and aspartate side chains. Many cosmetic peptides deal with this by attaching a fatty-acid tail — the palmitoyl prefix on Matrixyl, palmitoyl tripeptide-1 and palmitoyl tripeptide-38 exists for exactly this reason. Tripeptide-10 citrulline carries no such modification. Its 530 daltons is on the favourable side as peptides go, but nobody has published penetration or dermal-delivery data for it, so whether enough reaches the dermis to engage collagen fibrils in living skin is unknown.
What concentration is used, and how would I know?
You generally cannot know. Suppliers typically provide cosmetic peptides as dilute solutions and formulators add them at low single-digit percentages of that solution, meaning the actual peptide concentration in a finished product is a small fraction of a percent. INCI labelling lists ingredients in descending order only down to one percent, below which order is unregulated — so a peptide appearing near the end of the list could be present at almost any concentration beneath that threshold. No published study establishes a dose-response relationship for tripeptide-10 citrulline, so even a disclosed concentration could not be checked against an effective one.
Is it worth pairing with other peptides?
Pairing is how it is usually sold, and the only human study tested it that way. The pairing logic is reasonable on its face: tripeptide-10 citrulline targets structural collagen organisation in the dermis, while acetyl hexapeptide-3 (Argireline) and acetyl octapeptide-3 (SNAP-8) target neuromuscular expression lines through SNARE-complex interference. Different mechanisms, different wrinkle types, no obvious interference. The Raikou trial found some combination comparisons significant, but with six per arm it could not establish synergy, and its authors said the mechanism of any synergy was not clear. Treat combination as sensible formulation practice rather than a demonstrated multiplier.
Who Tripeptide-10 Citrulline Is NOT For
- •Known hypersensitivity to the peptide or, far more commonly, to other components of the finished formulation.
- •Active dermatitis, eczema, or broken or inflamed skin, where barrier disruption makes absorption and irritant potential unpredictable.
- •Immediately after ablative or fractional resurfacing, chemical peels or microneedling, until the barrier has recovered and the treating clinician approves resuming actives.
- •Not for use around the eyes unless the product is specifically formulated and tested for the eye area.
- •Pregnancy and breastfeeding have not been studied; systemic exposure from topical cosmetic use is expected to be negligible, but anyone wanting certainty should ask their clinician rather than rely on that expectation.
Drug & Supplement Interactions
No drug-interaction studies exist for tripeptide-10 citrulline, and meaningful systemic interaction is implausible — this is a hydrophilic peptide applied topically at a fraction of a percent, with no demonstrated systemic absorption. The interactions worth considering are topical and formulation-level rather than pharmacological. The realistic concern is irritation stacking. Peptide serums are frequently layered with retinoids, alpha and beta hydroxy acids, benzoyl peroxide or high-strength vitamin C, and the cumulative barrier disruption from that combination causes far more trouble than any individual ingredient. Where a routine includes a prescription retinoid or an acid exfoliant, separating applications by time of day is more sensible than stacking. Two formulation notes follow from the peptide's chemistry. It is hydrophilic and unmodified, so it belongs in the water phase and sits beneath occlusive layers rather than above them. And combination with other cosmetic peptides is the norm rather than an interaction risk: the mechanisms proposed for tripeptide-10 citrulline (dermal collagen fibril organisation) and for acetyl hexapeptide-3 or acetyl octapeptide-3 (SNARE-complex interference at the neuromuscular junction) are unrelated, with no basis for antagonism — and no demonstrated synergy either, as the authors of the only trial to test the combination explicitly noted.
Safety Profile
Common Side Effects
Cautions
- • The safety record rests on 24 participants over 60 days in a single trial. Absence of reported adverse events at that sample size is weak reassurance, not a safety database.
- • Patch-test any new leave-on product on a small area first, particularly on sensitive or compromised skin.
- • Avoid application to broken, inflamed or actively eczematous skin, where barrier disruption changes absorption unpredictably.
- • No data exist on use in pregnancy or breastfeeding. Systemic exposure from topical cosmetic use is likely to be negligible, but that is an inference rather than a measurement.
- • This is a cosmetic ingredient, not a drug. It is not intended to treat any dermatological condition, and visible photoageing, actinic damage or pigmentary disorders warrant a dermatologist rather than a peptide serum.
What We Don't Know
Almost everything beyond the in vitro fibrillogenesis result. There is no published skin-penetration or dermal-bioavailability data, no dose-response curve, no histological confirmation that collagen fibril diameter changes in living human skin, no long-term use data, and no independent replication of the original finding. The claimed benefit — better-organised collagen — has no validated non-invasive human measurement, which means it is a structural claim that current cosmetic trial methodology cannot directly test. Instrument-measured skin roughness, the endpoint actually used, is several inferential steps removed from fibril architecture.
Legal Status
United States
Regulated as a cosmetic ingredient by the FDA, not as a drug. Cosmetic ingredients other than colour additives require no premarket approval, and the FDA has not evaluated tripeptide-10 citrulline for safety or efficacy. The practical boundary is the claim: a product may say it improves the appearance of skin, but a claim to treat, prevent or alter the structure of skin would make it an unapproved new drug. There is no FDA-approved drug containing this peptide.
International
Listed in the European Commission's CosIng database under reference 83256 with the declared function of skin conditioning, and subject to the general safety requirements of the EU Cosmetic Products Regulation. It appears in no annex of restricted or prohibited substances, and no concentration limit applies. The ingredient is legal in cosmetics in all major markets, with the usual market-specific registration requirements for finished products.
Sports & Competition
Not on the WADA Prohibited List under any name, and no prohibited class reaches it. It is a topically applied cosmetic peptide with no systemic exposure, no hormonal activity and no plausible performance effect.
Regulatory status changes over time. Verify current local rules with a qualified professional.
Myths & Misconceptions
Myth
Tripeptide-10 citrulline is a tripeptide.
Reality
It is a tetrapeptide: lysine, aspartate, isoleucine and citrulline — four residues, molecular formula C22H42N8O7, about 530 daltons. The INCI convention counts only the three standard proteinogenic residues, which together form the separately registered ingredient Tripeptide-10, and names citrulline separately because it is not one of the twenty amino acids used in protein synthesis. The paper that introduced the molecule calls it a decorin-like tetrapeptide in its own title. This is a naming artefact rather than an error in any product, but it means the ingredient name is an unreliable guide to the chemistry.
Myth
It boosts collagen production.
Reality
It is specifically not designed to. The published premise is the opposite: skin collagen quality is addressed rather than skin collagen quantity. Decorin, the target being imitated, constrains collagen fibril diameter by binding the fibril surface and limiting lateral growth — an organising function, not a synthetic one. The in vitro data report thinner and more uniform fibres, with no measurement of collagen synthesis. Products describing tripeptide-10 citrulline as collagen-boosting are borrowing the mechanism of matrikine peptides such as Matrixyl or Syn-Coll, which really are proposed to upregulate procollagen synthesis. Conflating them erases the one thing that makes this ingredient distinctive.
Myth
The citrulline provides the benefits of citrulline supplements.
Reality
There is no connection beyond the word. Oral L-citrulline and citrulline malate are free amino acids taken in gram quantities that convert to arginine and feed nitric-oxide synthesis, producing vasodilation and the effects that interest athletes. The citrulline in tripeptide-10 citrulline is a single residue bonded into a peptide chain, applied topically at a fraction of a percent, not liberated as free citrulline, not entering the urea cycle, and not involved in nitric-oxide signalling at all. Marketing that implies circulation or blood-flow benefits from the citrulline component is describing a different molecule in a different route of administration.
Myth
Decorinyl replaces decorin in the skin.
Reality
It reproduces, at most, one binding interface of a much larger molecule. Decorin is a proteoglycan with a roughly 40-kilodalton leucine-rich-repeat core protein in a horseshoe conformation plus a glycosaminoglycan chain, and its functions extend beyond collagen binding to interfibrillar spacing and growth-factor sequestration. A four-residue, 530-dalton peptide can imitate a binding motif; it cannot substitute for the protein. The supplier framing of a substitute for non-functional decorin is a reasonable shorthand for the design intent and a poor description of the biology.
Myth
It is clinically proven to reduce wrinkles.
Reality
The evidence is one randomised trial with six participants per arm. Raikou and colleagues (2017) randomised 24 volunteers across four groups for 60 days and concluded that antiwrinkle efficacy had been shown — a reasonable description of their own nominally significant between-group differences, and a thin basis for the word proven. The endpoints were instrument-measured skin microtopography and transepidermal water loss rather than clinical or photographic wrinkle grading; the study has never been replicated; and it remains, nine years on, the only human trial of the ingredient in the published literature. It deserves credit for being independent of the supplier, which is more than most cosmetic peptide evidence can claim.
Published Research
7 studiesThe efficacy study of the combination of tripeptide-10-citrulline and acetyl hexapeptide-3. A prospective, randomized controlled study.
The only human trial of the ingredient, and independent of the supplier — the authors are at the Technological Educational Institute of Athens and the University of Athens. Twenty-four volunteers were randomised across four arms for 60 days: both peptides, tripeptide-10 citrulline alone, acetyl hexapeptide-3 alone, or neither. Endpoints were skin microtopography (cR2, cR3) by Visioscan and transepidermal water loss by Tewameter. Several between-group comparisons reached nominal significance and the authors concluded antiwrinkle efficacy had been shown for tripeptide-10 citrulline. The sample is six participants per arm, the endpoints are instrument surrogates, and the authors state the mechanism of any synergy was not clear.
A new decorin-like tetrapeptide for optimal organization of collagen fibres.
The discovery paper, by Lipotec researchers in Gava, Barcelona. Two tetrapeptide sequences were identified as decorin's specific collagen-binding sites; a focused library of mimetic tetrapeptides was synthesised and screened in an in vitro collagen fibrillogenesis assay, and the candidate given the INCI name Tripeptide-10 Citrulline performed best — regulating fibrillogenesis and producing thinner, more uniform collagen fibres. The paper's own framing is that skin collagen quality is addressed rather than collagen quantity. Note that the title calls it a tetrapeptide, contradicting the INCI name, and that the work is cell-free and conducted by the ingredient's manufacturer.
Structural change in decorin with skin aging.
The role of decorin in collagen fibrillogenesis and skin homeostasis.
Role of decorin on in vitro fibrillogenesis of type I collagen.
Targeted disruption of decorin leads to abnormal collagen fibril morphology and skin fragility.
Model structure of decorin and implications for collagen fibrillogenesis.
Quick Facts
- Class
- Cosmetic Signal Peptide (Decorin-Mimetic Tetrapeptide)
- Tier
- C
- Evidence
- Preliminary
- Safety
- Limited Data
- Updated
- Oct 2026
- Citations
- 7PubMed
Also known as
Tags
Peptide Families
Related Goals
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.